Below are the most recent publications written about "Sodium-Glucose Transporter 2" by people in Profiles.
-
Duan HY, Barajas-Martinez H, Antzelevitch C, Hu D. The potential anti-arrhythmic effect of SGLT2 inhibitors. Cardiovasc Diabetol. 2024 07 15; 23(1):252.
-
Prebay ZJ, Foss H, Ebbott D, Hyman J, Li M, Chung PH. Do Sodium-Glucose Co-Transporter 2 Inhibitors Increase the Risk of Urologic Implant Reintervention? Urology. 2023 04; 174:191-195.
-
Moellmann J, Mann PA, Kappel BA, Kahles F, Klinkhammer BM, Boor P, Kramann R, Ghesquiere B, Lebherz C, Marx N, Lehrke M. The sodium-glucose co-transporter-2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR signalling, endoplasmic reticulum stress and apoptosis. Diabetes Obes Metab. 2022 11; 24(11):2263-2272.
-
Sabouret P, Bocchino PP, Angelini F, D'Ascenzo F, Galati G, Fysekidis M, DE Ferrari GM, Fischman DL, Bhatt DL, Biondi-Zoccai G. Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis. Minerva Cardiol Angiol. 2023 04; 71(2):199-207.
-
Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, Khariton Y, Malik AO, Khumri T, Umpierrez G, Lamba S, Sharma K, Khan SS, Chandra L, Gordon RA, Ryan JJ, Chaudhry SP, Joseph SM, Chow CH, Kanwar MK, Pursley M, Siraj ES, Lewis GD, Clemson BS, Fong M, Kosiborod MN. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021 11; 27(11):1954-1960.
-
Moellmann J, Klinkhammer BM, Droste P, Kappel B, Haj-Yehia E, Maxeiner S, Artati A, Adamski J, Boor P, Sch?tt K, Lopaschuk GD, Verma S, Marx N, Lehrke M. Empagliflozin improves left ventricular diastolic function of db/db mice. Biochim Biophys Acta Mol Basis Dis. 2020 08 01; 1866(8):165807.
-
Jabbour S. Durability of response to dapagliflozin: a review of long-term efficacy and safety. Curr Med Res Opin. 2017 09; 33(9):1685-1696.
-
Baker WL, Buckley LF, Kelly MS, Bucheit JD, Parod ED, Brown R, Carbone S, Abbate A, Dixon DL. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2017 May 18; 6(5).
-
Fortuna D, McCloskey LJ, Stickle DF. Model analysis of effect of canagliflozin (Invokana), a sodium-glucose cotransporter 2 inhibitor, to alter plasma 1,5-anhydroglucitol. Clin Chim Acta. 2016 Jan 15; 452:138-41.
-
Dardi I, Kouvatsos T, Jabbour SA. SGLT2 inhibitors. Biochem Pharmacol. 2016 Feb 01; 101:27-39.